Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) Trial

Background In recent large cardiovascular trials done in stable patients, 14-31% of the participants were smokers; the consequences of smoking in these trials using medications known to reduce cardiovascular events, have not been assessed. Design We evaluated the cardiovascular outcomes according to smoking status of men and women participating in the Heart Outcomes Prevention Evaluation trial. Methods The occurrence of cardiovascular events was documented among participants who did not change their smoking status during the trial. There were 2728 ‘never smokers’, 5241 ‘former smokers’ and 936 ‘current smokers’, and all had stable cardiovascular disease or diabetes with at least one other risk factor. None had previous congestive heart failure or known left ventricular ejection fraction < 0.40. Results During the 4.5-year follow-up, there were 641 cardiovascular deaths, 978 myocardial infarctions, 358 strokes and 1021 deaths. In comparison to ‘never smokers’, smokers had relative risks adjusted for confounding variables including medications known to reduce cardiovascular mortality and morbidity, for cardiovascular death of 1.65 [95% confidence interval (CI), 1.28-2.14], for myocardial infarction of 1.26 (95% CI, 1.01-1.58), for stroke of 1.42 (95% CI, 1.00-2.04), and for total mortality of 1.99 (95% CI, 1.63-2.44). The rates of these events among ‘former smokers’ were not different from those of ‘never smokers’. Conclusions Smoking increased the risk of mortality and morbidity among high-risk patients despite the use of medications known to reduce cardiovascular events. Smoking cessation programs should be reinforced even for patients participating in clinical trials.

[1]  R. Bergström,et al.  Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. , 2009, Acta medica Scandinavica.

[2]  J. Ambrose,et al.  The pathophysiology of cigarette smoking and cardiovascular disease: an update. , 2004, Journal of the American College of Cardiology.

[3]  Y. Kupfer,et al.  Valsartan, captopril, or both in myocardial infarction. , 2004, New England Journal of Medicine.

[4]  K. Haustein.  What can we do in secondary prevention of cigarette smoking? , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[5]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[6]  A. Tenenbaum,et al.  Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. , 2003, Archives of internal medicine.

[7]  Majid Ezzati,et al.  Estimates of global mortality attributable to smoking in 2000 , 2003, The Lancet.

[8]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[9]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[10]  S. Yusuf.  Two decades of progress in preventing vascular disease , 2002, The Lancet.

[11]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[12]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[13]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[14]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[15]  K. Muir,et al.  Stress, social support, and stopping smoking after myocardial infarction in England. , 1995, Journal of epidemiology and community health.

[16]  T. Pearson.  Primer in Preventive Cardiology , 1994 .

[17]  Diane C. Thompson,et al.  The validity of self-reported smoking: a review and meta-analysis. , 1994, American journal of public health.

[18]  J Bamford,et al.  Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. , 1994, Stroke.

[19]  B. Gersh,et al.  Effect of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the coronary artery surgery study (CASS): 10-Year follow-up , 1992 .

[20]  S. Wacholder,et al.  The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. , 1984, The New England journal of medicine.

[21]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[22]  S M Ernst,et al.  Smoking and cardiac events after venous coronary bypass surgery. A 15-year follow-up study. , 1996, Circulation.

[23]  B. Gersh,et al.  Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. CASS Investigators. , 1992, Journal of the American College of Cardiology.